ArticleCVIR endovascular2026
Diagnostic and therapeutic utility of ethiodized oil-based lymphangiography in pelvic and groin lymphatic leaks.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thoracic and retroperitoneal lymphatic injuries following spine surgery: illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPelvic and groin lymphoceles and lymphatic leaks remain challenging postsurgical complications. Ethiodized-oil (lipiodol) lymphangiography has been increasingly utilized as a combined diagnostic and therapeutic modality, but published experience with lipiodol-only management in this setting is limited. While transnodal glue embolization is well established, evidence on its long-term outcomes and safety profile remains sparse, with particular concerns regarding the potential risk of lymphedema. These gaps highlight the need for further evaluation of lymphangiography alone as a minimally invasive treatment option. MATERIALS AND
methodsThis retrospective study included patients who underwent lymphangiography between January 2019 and March 2023 for persistent symptomatic pelvic lymphoceles or groin lymphatic leaks. Imaging findings, drain output, prior interventions, and clinical outcomes were reviewed. Technical success was defined as adequate visualization of the targeted lymphatic vessels. Clinical success was defined as resolution or minimal residual leak without need for further treatment.
resultsTen patients (5 males, median age, 69 years) underwent lymphangiography for pelvic lymphoceles (n = 7) or groin lymphatic leaks (n = 3). The median interval from surgery to INL was 67.5 days (range, 12-108). Three patients had previously undergone surgical interventions, and four patients had undergone sclerotherapy without clinical improvement before INL was performed. Technical success was achieved in all patients (100%) with identification of lymphatic leak in all patients. Clinical success was achieved in 7 patients (70%) following lymphangiography alone, with a median time to resolution of 5.5 days (range, 5-12 days) and no immediate adverse events.
conclusionsLymphangiography using ethiodized oil contrast is a safe, and potentially effective minimally invasive treatment for pelvic and groin lymphatic leaks. These findings support a stepwise management approach, using lymphangiography as a first-line intervention before escalating to intranodal glue embolization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.